Filling the need for trusted information on national health issues…

Discontinuing Antibiotic Used To Prevent Opportunistic Infections Among HIV Patients Could Increase Risk Of Malaria, Diarrhea

“Abruptly discontinuing co-trimoxazole — an antibiotic used to prevent opportunistic infections in HIV-positive people — can lead to a higher incidence of malaria and diarrhea compared with patients who keep on taking the drug,” according to a study conducted by the CDC in eastern Uganda and published by the Oxford Journal of Clinical Infectious Diseases in March, PlusNews reports. “The researchers found that 72 percent of the 315 cases of fever reported by study participants occurred among those who had stopped taking co-trimoxazole prophylaxis, and they were also nearly twice more likely to report diarrhea,” the news service notes.

“‘The findings most likely mean that HIV-infected persons, while on co-trimoxazole, have a lower rate of these infectious diseases, and stopping the drug increases the rate,’ James Campbell, lead researcher of the study and director of science at CDC Uganda, told IRIN/PlusNews,” the news service writes. “Co-trimoxazole is relatively cheap, but the researchers note that lifetime prophylaxis using the drug may have cost and toxicity implications,” PlusNews notes, adding, “Campbell said, ‘Important questions include the effect of more frequent malaria and diarrhea episodes on the longer-term outcomes of HIV infection, the longer-term risks of inducing or selecting for resistant micro-organisms, and comparing antimicrobial prophylaxis to other means of reducing the risk of malaria and diarrhea in this population'” (4/11).

The Henry J. Kaiser Family Foundation Headquarters: 2400 Sand Hill Road, Menlo Park, CA 94025 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in Menlo Park, California.